Novofine Autocover Safety Needle Versus BD Safety Glide

This study has been completed.

First Received: July 13, 2005 Last Updated: October 2, 2009 History of Changes

Sponsor:	Novo Nordisk
Information provided by:	Novo Nordisk
ClinicalTrials.gov Identifier:	NCT00121355

Purpose

This study will examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether these hospital nurses prefer the safety features of the NovoFine® Autocover Needle versus those of the BD Safety Glide (TM) Syringe. The identified hospital nurses will evaluate the two types of needles during standard administration of insulin to patients being treated for diabetes.

Condition	Intervention	Phase
Health Personnel	Device: safety glide Device: autocover needle	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Crossover Assignment, Safety Study

Further study details as provided by Novo Nordisk:

Enrollment:	83
Study Start Date:	July 2005
Study Completion Date:	June 2006
Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Hospital nurses with prior injection training without an infectious blood borne disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00121355

Locations

United States, Florida
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33176
United States, Georgia
Novo Nordisk Clinical Trial Call Center
Atlanta, Georgia, United States, 30339
United States, Louisiana
Novo Nordisk Clinical Trial Call Center
New Orleans, Louisiana, United States, 70121
United States, Ohio
Novo Nordisk Clinical Trial Call Center
Cleveland, Ohio, United States, 44195
Novo Nordisk Clinical Trial Call Center
Portsmouth, Ohio, United States, 45662
Novo Nordisk Clinical Trial Call Center
Zanesville, Ohio, United States, 43701
Novo Nordisk Clinical Trial Call Center
Westerville, Ohio, United States, 43081
United States, Texas
Novo Nordisk Clinical Trial Call Center
Irving, Texas, United States, 75061
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

Novo Nordisk

Investigators

Study Director:

Campbell Howard, MD

Novo Nordisk

More Information

Additional Information:

Clinical Trials at Novo Nordisk This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Novo Nordisk A/S ( Public Access to Clinical Trials )
Study ID Numbers:	MS241-1674
Study First Received:	July 13, 2005
Last Updated:	October 2, 2009
ClinicalTrials.gov Identifier:	NCT00121355 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Novo Nordisk:

Needles

ClinicalTrials.gov processed this record on February 08, 2010